Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma

Marwa Mohammed Hasan Tawfik,Aya Yassin,Ahmed Mohamed Monib,Susan Adil Ali

doi:10.1186/s43055-020-00203-4

Marwa Mohammed Hasan Tawfik, Aya Yassin + Show 2 more

Open Access

https://doi.org/10.1186/s43055-020-00203-4

Copy DOI

Abstract

BackgroundAccurate radiologic assessment of treatment response in lymphomas is important for helping the clinicians to properly evaluate effectiveness of treatment and consequently guide therapeutic management of these patients. Imaging tools based on anatomic response are suboptimal in detecting functional changes in tumors resulting after early effective treatment. Recently, with the development of 18F-FDG PET/CT, both functional and anatomic information has been integrated for assessing treatment response in both solid tumors and hematologic malignancies. The aim of this study was to compare therapeutic response in lymphoma patients using both RECIST 1.1 and PERCIST 1.0 criteria.ResultsAmong the included 33 lymphoma patients, RECIST 1.1 and PERCIST 1.0 classifications of therapeutic response were concordant in 20 patients (60.6%) and discordant in 13 patients (39.4%), with a tendency of RECIST 1.1 to downgrade the tumor response in 12/13 patients (P value < 0.001).ConclusionThe recently applied PERCIST 1.0 is efficient and more accurate than RECIST 1.1 to assess treatment response in lymphoma patients, which is subsequently affecting further management of these patients.

Highlights

Accurate radiologic assessment of treatment response in lymphomas is important for helping the clinicians to properly evaluate effectiveness of treatment and guide therapeutic management of these patients
The currently accepted standard anatomic response classifications are Response evaluation criteria in solid tumor (RECIST) and RECIST 1.1; they do not have the ability to detect functional changes in tumors resulting after early effective treatment [3]. 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography
Fifteen patients presented with histopathologically proven non-Hodgkin lymphoma, 17 patients had Hodgkin lymphoma, and 1 patient with Gutassociated lymphoid tissue (GALT)

Summary

Introduction

Accurate radiologic assessment of treatment response in lymphomas is important for helping the clinicians to properly evaluate effectiveness of treatment and guide therapeutic management of these patients. The currently accepted standard anatomic response classifications are Response evaluation criteria in solid tumor (RECIST) and RECIST 1.1; they do not have the ability to detect functional changes in tumors resulting after early effective treatment [3]. It is important to report the change in standardized uptake value (SUV) in initial and follow-up scans as the PET biologic predictive value of PET is much greater than that of anatomic studies [8,9,10] This is done by using PET response criteria in solid tumor (PERCIST criteria) depending on standardized uptake value changes by the tumoral mass [11]. Aim of this work was to compare between anatomical post-therapeutic response by contrast-enhanced CT with applied RECIST 1.1 criteria and combined qualitative and quantitative metabolic response by 18F-FDG PET/CT with applied PERCIST 1.0 criteria in lymphoma patients

Methods

Results

Discussion

Conclusion